• Earlier in 2026, CorMedix Inc. reported strong Q1 results driven by DefenCath and raised its full-year 2026 guidance while outlining progress on late-stage programs such as REZZAYO.
• Management also emphasized continued business momentum even as the company prepares for the expiration of temporary TDAPA reimbursement, highlighting execution in a changing reimbursement backdrop.
• Next, we will examine how CorMedix's raised 2026 guidance and DefenCath’s contribution shape the company’s broader investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is CorMedix's Investment Narrative?

To own CorMedix today, you have to believe DefenCath can remain a durable cash engine while the company carefully broadens into hospital anti-infectives like REZZAYO. The latest Q1 beat and higher 2026 revenue guidance reinforce DefenCath’s importance and suggest that near-term catalysts are still mostly commercial: sustaining uptake, managing formulary access and keeping margins healthy. The new REZZAYO data adds a meaningful clinical and regulatory milestone, but it is a medium-term story, with any financial impact likely to build gradually rather than change the next few quarters overnight. In the near term, the more immediate swing factor remains how CorMedix absorbs the eventual TDAPA expiration and any pricing or volume pressure that follows. The recent results help, but they do not remove that uncertainty.

However, one risk stands out that investors should not overlook around TDAPA expiring. CorMedix's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Nine fair value views from the Simply Wall St Community span roughly US$12 to a very large US$734, showing how far opinions stretch. Against that backdrop, CorMedix’s dependence on DefenCath reimbursement and the coming TDAPA shift places real weight on how each of these scenarios could play out for future performance. You are seeing very different expectations that are worth comparing carefully.

Explore 9 other fair value estimates on CorMedix - why the stock might be worth just $12.00!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CorMedix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CorMedix's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.